MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.68 1.52

Overview

Share price change

24h

Current

Min

2.65

Max

2.69

Key metrics

By Trading Economics

Income

-6.4M

-53M

Sales

-9.6M

47M

EPS

-0.02

Profit margin

-112.813

Employees

580

EBITDA

-28M

-49M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+72.28% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

106M

880M

Previous open

1.16

Previous close

2.68

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jul 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 Jul 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 Jul 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 Jul 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 Jul 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 Jul 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 Jul 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 Jul 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 Jul 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 Jul 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

72.28% upside

12 Months Forecast

Average 4.6 USD  72.28%

High 7 USD

Low 2 USD

Based on 7 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

4

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.